Last reviewed · How we verify
NCT04517175
Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics?
trial testing Flow cytometry in Myelodysplastic Syndromes in 300 participants. Status unknown.
1 September 2025
Quick facts
| Lead sponsor | Maastricht University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 September 2020 |
| Primary completion | 1 September 2025 |
| Estimated completion | 1 September 2025 |
Drugs / interventions tested
- Flow cytometry
Conditions studied
- Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →
- Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
- Myelodysplastic Syndrome/Neoplasm — all drugs for Myelodysplastic Syndrome/Neoplasm →
Sponsor
Maastricht University
Who can join
18 and older, any sex, with Myelodysplastic Syndromes or Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Ki-67 is used as a marker for determination of the proliferative activity in solid tumors. The use within hemato-oncological malignancies is limited. This is related to limited technical possibilities of flow cytometry in the past. Meanwhile, flow cytometry in hemato-oncological malignancies has progressed to assessment of 8 colors and makes it possible to add Ki-67 as an additional marker to the 8-color panels. Adding Ki-67 to these panels could lead to improved diagnosis and prediction of therapy response for a number of hemato-oncological malignancies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04517175
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Flow cytometry
Trials testing the same drug.
- NCT06925958 — A Clinical Trial Evaluating the Safety Tolerability, Radiation Absorption Dose, Distribution, PET Imaging and Histologic · NA · not yet recruiting
- NCT06352515 — T Lymphocyte Subsets in Ulcerative Colitis · not yet recruiting
- NCT06160115 — The Role of NK Cells to Detect Blood Infection in ALL. · unknown
- NCT06460142 — Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic · recruiting
- NCT05848986 — Study if the Presence of Functional FcERI/RII on the Surface of Human Blood Platelet · unknown
Other recruiting trials for Myelodysplastic Syndromes
Currently open trials in the same condition.
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT06303193 — Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or · Phase 1, PHASE2 · recruiting
- NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting
- NCT07283900 — Ascorbate in Myelodysplastic Syndrome · Phase 2 · recruiting
- NCT06487247 — HEME Home Transfusion Program · NA · recruiting
Other Maastricht University trials
Trials by the same sponsor.
- NCT07417059 — Sex Hormones Impact on Cannabis Response · NA · recruiting
- NCT07259005 — Breathe Hard to Breathe Easy: Online Breathwork-Assisted Therapy for Social Anxiety · NA · recruiting
- NCT06914648 — The Dragon PLC Trial (DRAGON-PLC) · NA · recruiting
- NCT07374926 — The Big Unknown: A Journey Into Generative AI's Transformative Effect on Medical Professions · NA · completed
- NCT06031818 — Usability and Clinical Effectiveness of an Interpretable Deep Learning Framework for Post-Hepatectomy Liver Failure Pred · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04517175 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Maastricht University
- Last refreshed: 18 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04517175.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing